ArticleBMC infectious diseases2017
Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Impact of Active Versus Passive Surveillance on Hepatitis C Virus Testing Uptake, Diagnosis and Linkage to Care in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.Tropical medicine & international health : TM & IH · 2026Pooled it
- Development and application of a real-time VPCR method for ultra-fast quantitative analysis and Visual Detection of HBV-DNA.Journal of clinical microbiology · 2026Article
- Comparison of Antibody Confirmation Assays for Hepatitis C Virus Testing in Patients With HIV.Sexually transmitted diseases · 2025Article
- A robust DNA walker for simplified, rapid, and sensitive detection of HBV DNA in blood.Mikrochimica acta · 2025Article
- Understanding Barriers to Hepatitis C Antiviral Treatment in Low-Middle-Income Countries.Healthcare (Basel, Switzerland) · 2024Review
- Molecular Point-of-Care Testing for Hepatitis C: Available Technologies, Pipeline, and Promising Future Directions.The Journal of infectious diseases · 2024Review
- Survey of lived experiences and challenges in hepatitis B management and treatment.BMC public health · 2024Article
- CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients.Emerging microbes & infections · 2023Article
- Barriers to hepatitis B virus screening of pregnant women in primary healthcare centers in Nigeria: health workers' perspective.BMC primary care · 2023Article
- Facilitators and barriers to in vitro diagnostics implementation in resource-limited settings: A scoping review.African journal of primary health care & family medicine · 2023Article
- A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016 - 2021.BMC public health · 2022Article
- Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific.HIV medicine · 2022Article
- Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies.Viruses · 2021Review
- The role of a two-assay serological testing strategy for anti-HCV screening in low-prevalence populations.Scientific reports · 2021Article
- Diagnostic Performance and Usability of the GenedriveDiagnostics (Basel, Switzerland) · 2021Article
- Eliminating mother-to-child transmission of human immunodeficiency virus, syphilis and hepatitis B in sub-Saharan Africa.Bulletin of the World Health Organization · 2021Article
- Retrospective Evaluation of Hepatitis C Awareness in Turkey Through Two Decades.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021Article
- From risk to care: the hepatitis C screening and diagnostic cascade in a primary health care clinic in Karachi, Pakistan-a cohort study.International health · 2020Article
- Article
- Towards better diagnostic tools for liver injury in low-income and middle-income countries.BMJ global health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccess to hepatitis B virus (HBV) and hepatitis C virus (HCV) diagnostics remains a key bottleneck in scale-up of access to HBV and HCV treatment, particularly in low- and middle-income countries (LMICs) that lack laboratory resources and skilled personnel. To inform the development of World Health Organization (WHO) testing guidelines on who to test and how to test, we performed a "values and preferences" survey of end users and implementers of hepatitis testing in LMICs on current hepatitis B and C testing practices and acceptability of diagnostic approaches, as well as preferences for the future.
methodsThe survey consisted of a four-part, 28 question online survey tool using SurveyMonkey software. The invitation to participate was sent via email to a network of contacts in hepatitis clinical care, research, advocacy and industry.
resultsThe survey collected responses on current testing practices from 48 respondents in 23 LMICs. Only a small proportion of hepatitis testing is currently funded through government-supported programmes. Most limit their testing programmes to blood donor screening and although testing is recommended in several populations, this is not well implemented. Also, there is still very limited access to virological testing.
conclusionsThe survey showed that HBV and HCV testing programmes in LMICs are inadequate and/or scarce. Lack of affordable diagnostic tests; lack of funding, public education and awareness; absence of national policies and guidelines; and a dearth of skilled health professionals are the most important barriers to scaling up HBV and HCV diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.